PRA Health Sciences (NASDAQ:PRAH) Upgraded at BidaskClub

PRA Health Sciences (NASDAQ:PRAH) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, BidAskClub reports.

A number of other brokerages have also recently commented on PRAH. Robert W. Baird boosted their price target on PRA Health Sciences from $119.00 to $122.00 and gave the stock an “outperform” rating in a research report on Thursday, February 28th. Wolfe Research began coverage on PRA Health Sciences in a research report on Tuesday, April 2nd. They issued a “market perform” rating on the stock. SunTrust Banks boosted their price target on PRA Health Sciences to $120.00 and gave the stock an “average” rating in a research report on Monday, March 4th. ValuEngine cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Finally, Mizuho set a $100.00 price target on PRA Health Sciences and gave the stock a “hold” rating in a research report on Friday, May 3rd. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. PRA Health Sciences presently has an average rating of “Buy” and an average target price of $113.22.

Shares of PRAH traded down $0.49 during mid-day trading on Friday, reaching $95.93. The company had a trading volume of 463,195 shares, compared to its average volume of 614,049. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.12. PRA Health Sciences has a 52 week low of $82.12 and a 52 week high of $121.98. The stock has a market cap of $6.33 billion, a P/E ratio of 24.41, a P/E/G ratio of 1.30 and a beta of 1.08.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.15. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. The firm had revenue of $722.00 million for the quarter, compared to analysts’ expectations of $730.84 million. During the same period in the previous year, the firm posted $0.85 EPS. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. On average, equities analysts anticipate that PRA Health Sciences will post 4.63 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Carroll Financial Associates Inc. lifted its position in PRA Health Sciences by 7.6% in the 1st quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock valued at $167,000 after acquiring an additional 107 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in PRA Health Sciences by 1.3% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,390 shares of the medical research company’s stock valued at $1,146,000 after acquiring an additional 129 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in PRA Health Sciences by 1.6% in the 1st quarter. Crossmark Global Holdings Inc. now owns 8,840 shares of the medical research company’s stock valued at $975,000 after acquiring an additional 140 shares in the last quarter. Kendall Capital Management lifted its position in PRA Health Sciences by 1.5% in the 1st quarter. Kendall Capital Management now owns 9,907 shares of the medical research company’s stock valued at $1,093,000 after acquiring an additional 142 shares in the last quarter. Finally, BB&T Securities LLC lifted its position in PRA Health Sciences by 3.5% in the 4th quarter. BB&T Securities LLC now owns 4,240 shares of the medical research company’s stock valued at $389,000 after acquiring an additional 145 shares in the last quarter. 99.43% of the stock is currently owned by institutional investors and hedge funds.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: Why is Cost of Capital Important?

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit